Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Choline Chloride for Injection (Low Dose and High Dose) Versus Placebo in Adolescents and Adults With Intestinal Failure Receiving Long-Term Parenteral Support

NCT06910943 is registered in ClinicalTrials.gov with Protara Therapeutics as lead sponsor.

NCT NCT06910943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06910943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Choline Chloride for Injection (Low Dose and High Dose) Versus Placebo in Adolescents and Adults With Intestinal Failure Receiving Long-Term Parenteral Support
Lead sponsor
Protara Therapeutics
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 10, 2025
Completion date
January 31, 2029
Enrollment
129 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

choline deficiency, liver injury